12:00 AM
 | 
Apr 29, 2013
 |  BC Week In Review  |  Company News  |  Deals

Perosphere, Daiichi Sankyo deal

Daiichi Sankyo will co-sponsor a Phase I trial evaluating Perosphere's PER977 to reverse the anticoagulant activity of Daiichi Sankyo's edoxaban. PER977 is a small molecule...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >